AbbVie Issues Inaugural Full-Year Outlook for 2013

PR Newswire/Les Echos/ 
AbbVie Issues Inaugural Full-Year Outlook for 2013 
- HUMIRA delivers 9th year of double-digit growth in 2012; forecasting low
double-digit growth in 2013 
- Advances 11 Phase III programs; HCV Phase III trials underway and on track 
for early 2015 launch 
- Pro vides full-year 2013 adjusted EPS guidance of $3.03 to $3.13 ($2.66 to
$2.76 on a GAAP basis) 
NORTH CHICAGO, Ill., Jan. 30, 2013 -- AbbVie (NYSE: ABBV) today confirmed it
delivered strong sales growth with its marketed pharmaceutical products in 
2012. The proprietary pharmaceutical segment of Abbott, representing the 
majority of AbbVie's revenue, grew more than 8 percent globally on an 
operational basis, excluding a nearly 3 percent negative impact from foreign 
Performance was driven by solid double-digit growth from both HUMIRA and
AndroGel and continued growth from the company's portfolio of market-leading
therapies, including Creon and Synthroid. 
Additionally, AbbVie is issuing adjusted earnings-per-share guidance for the
full-year 2013 of $3.03 to $3.13, or $2.66 to $2.76 on a Generally Accepted
Accounting Principles (GAAP) basis. The company's 2013 adjusted
earnings-per-share guidance excludes $0.37 per share of non-cash intangible
amortization expense and specified items, primarily associated with certain
separation-related costs and previously announced ongoing restructuring
"AbbVie's portfolio of marketed products delivered solid growth in 2012,
positioning us well for healthy performance in our first year as an independent
company," said Richard A. Gonzalez, chairman and chief executive officer,
AbbVie. "In 2013, we expect to deliver on AbbVie's key priorities of driving
continued strong growth of HUMIRA, maximizing our specialty product portfolio,
advancing our promising pipeline including our late-stage HCV program, and
delivering returns to shareholders through our strong dividend." 
Pipeline and Regulatory Milestones 
In addition to strong sales growth, in 2012 AbbVie continued to execute on its
regulatory and clinical objectives. This includes securing approvals for four
new HUMIRA indications; the addition of two promising mid-stage compounds,
including a next-generation JAK1 inhibitor and a novel therapy for acute kidney
injury; and the advancement of key development programs, including the start of
Phase III studies for our interferon-free Hepatitis C (HCV) combination and
AbbVie expects long-term growth will be fueled by a compelling pipeline of
therapies in development to address medical conditions with high unmet need. 
The company is focused on advancing a number of Phase III programs, including:
an interferon-free oral combination for HCV; daclizumab for relapsing remitting
multiple sclerosis (in partnership with Biogen); elagolix for endometriosis;
elotuzumab for multiple myeloma (in partnership with Bristol Myers Squibb); and
several new indications for HUMIRA. 
In 2013, the company expects to initiate several Phase III programs including
atrasentan for diabetic kidney disease and ABT-1 99 in chronic lymphocytic
leukemia (CLL). Additionally, AbbVie is planning Phase IIB starts for: elagolix
in uterine fibroids; our partnered JAK1 inhibitor (GLPG0634) for rheumatoid
arthritis (RA); BT-061 for RA; and ABT-719 for acute kidney injury associated
with major cardiac and other surgeries. Finally, in 2013, the company intends 
to present data from a number of key development programs, including our 
rapidly advancing HCV program, oncology, renal disease, immunology and 
Alzheimer's disease. 
Management to Discuss Company Performance and Outlook on Investor Call Today 
AbbVie will host an investor conference call today at 8 a.m. Central time to
discuss our fourthquarter and full-year 2012 highlights and 2013 outlook.
Participating on the call will be Rick Gonzalez, chairman and chief executive
officer; Bill Chase, executive vice president and chief financial officer; 
Laura Schumacher, executive vice president of business development, external 
affairs and general counsel; John Leonard, senior vice president and chief 
scientific officer; and Larry Peepo, vice president of investor relations. The 
call will be webcast through Abb Vie's Investor Relations website at An archived edition of the call will be available after
11 a.m. Central time. 
Key Product Performance: 

           Sales ($ in millions)
            U.S.  Int'l   Total                   % Change vs. 4Q11
                                              Int'l                Total

                             U.S. Operational Reported Operational Reported
HUMIRA    1,413   1,268   2,681  31.1      17.9      15.2     24.5       23.1
TriCor      202    --       202 (50.7)      n/a       n/a    (50.7)     (50.7)
AndroGel    364    --       364  40.5       n/a       n/a     40.5       40.5
Kaletra      83     167     250 (17.0)     (9.4)    (11.4)   (12.1)     (13.4)
Lupron      155      56     211  11.3     (17.4)    (18.1)     1.8        1.6
Niaspan     277    --       277   7.4       n/a       n/a      7.4        7.4
Synthroid   168    --       168  24.9       n/a       n/a     24.9       24.9
Creon       105    --       105   3.9       n/a       n/a      3.9        3.9 
The following is a summary of fourth-quarter 2012 sales for select AbbVie

           Sales ($ in millions)
            U.S.  Int'l   Total           % Change vs. 12M11
                                             Int'l                 Total

                             U.S. Operational Reported Operational Reported
HUMIRA     4,376  4,889   9,265  27.7    15.4         8.5     20.7        16.8
TriCor     1,098    --    1,098 (19.9)   n/a          n/a    (19.9)      (19.9)
AndroGel   1,152    --    1,152  31.7    n/a          n/a     31.7        31.7
Kaletra      280    733   1,013 (14.1)  (7.6)        (13.2)   (9.4)      (13.4)
Lupron       569    231     800   5.4  (10.5)        (14.4)    0.1        (1.2)
Niaspan      911    --      911  (6.7)   n/a          n/a     (6.7)       (6.7)
Synthroid    551    --      551   5.7    n/a          n/a      5.7         5.7
Creon        353    --      353   6.5    n/a          n/a      6.5         6.5 
Note: "Operational" growth reflects percentage change over the prior year
excluding the impact of exchange rates. 
About AbbVie
AbbVie is a global, research-based biopharmaceutical company formed in 2013
following separation from Abbott. With its 1 25-year history, the company's
mission is to use its expertise, dedicated people and unique approach to
innovation to develop and market advanced therapies that address some of the
world's most complex and serious diseases. In 2013, AbbVie employs 
approximately 21,000 people worldwide and markets medicines in more than 170 
countries. For further information on the company and its people, portfolio and
commitments, please visit Follow @abbvie on Twitter or 
view careers on our Facebook or LinkedIn page. 
Forward-Looking Statements
Some statements in this news release may be forward-looking statements for
purposes of the Private Securities Litigation Reform Act of 1995. AbbVie
cautions that these forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially from those
indicated in the forward-looking statements. Economic, competitive,
governmental, technological and other factors that may affect AbbVie's
operations are discussed in the "Risk Factors" section of the Information
Statement attached to our Form 10 Registration Statement, which has been filed
with the SEC, and are incorporated by reference. AbbVie undertakes no 
obligation to release publicly any revisions to forward-looking statements as 
a result of subsequent events or developments, except as required by law.

CONTACT: Media, Jennifer Smoter, +1-847-935-8865, or Greg Miley,
+1-847-938-4898, or Adelle Infante, +1-847-938-8745, or Investors, Larry Peepo,
+1-847-935-6722, or, Liz Shea, +1-847-935-2211 
The content and accuracy of news releases published on this site and/or 
distributed by PR Newswire or its partners are the sole responsibility of the 
originating company or organisation. Whilst every effort is made to ensure the 
accuracy of our services, such releases are not actively monitored or reviewed 
by PR Newswire or its partners and under no circumstances shall PR Newswire or 
its partners be liable for any loss or damage resulting from the use of such 
information. All information should be checked prior to publication. 
-0- Jan/31/2013 08:12 GMT
Press spacebar to pause and continue. Press esc to stop.